•The University of Texas at Dallas (UTD) /University of Texas System along with Southern Methodist University was awarded a patent in 2014 (USPTO Patent number: 8680094) entitled “1, 4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions”. Dr. D’Mello, Founder and CEO of Nerugeneron, is the sole UTD inventor in this patent. UTD has permitted Neugeneron to conduct research and development work on HSB-13. An agreement signed between the UTD and Neugeneron provides Neugeneron the option to obtain an exclusive license.
•The University of Texas at Dallas (UTD) /University of Texas System along with Southern Methodist University was awarded a patent in 2014 (USPTO Patent number: 8680094) entitled “1, 4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions”. Dr. D’Mello, Founder and CEO of Nerugeneron, is the sole UTD inventor in this patent. UTD has permitted Neugeneron to conduct research and development work on HSB-13. An agreement signed between the UTD and Neugeneron provides Neugeneron the option to obtain an exclusive license.
•A Provisional Patent application entitled “1,4-benzoxazines for the treatment of cancers and other neurodegenerative diseases” has been filed with the USPTO with, among other claims, the use of NGN-006 for the treatment of glioblastoma (USPTO application no. 63023544).
•A Provisional Patent application entitled “1,4-benzoxazines for the treatment of cancers and other neurodegenerative diseases” has been filed with the USPTO with, among other claims, the use of NGN-006 for the treatment of glioblastoma (USPTO application no. 63023544).